Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECTRA-SIRIO 2: Ticagrelor De-escalation in ACS
NCT04718025Phase 3Unknown
- Sponsor
- Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in acute coronary syndrome (ACS) (3 arms), sponsored by Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz. Primary endpoints: Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 12 months and Major Adverse Cardiovascular Events at 12 months. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04718025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718025.